본문 바로가기

Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatits B e Antigen-Positive Hepatitis B Patients: A Randomized, Multicenter, Phase IIIb Open-Label Study (POTENT Study)

Efficacy of pegylated interferon monotherapy versus sequential therapy of entecavir and pegylated interferon in Hepatitis B e antigen-Positive Hepatitis B Patients: A randomized, multicenter, phase IIIb Open-Label Study (POTENT Study)

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q1
저널
CHINESE MEDICAL JOURNAL131(14) · pp.1645 · 2018
피인용
Web of Science 7Scopus 8
FWCI (Scopus)
0.59
JCR IF
JCR 2017 1.596
ISSN
0366-6999

저자

  1. Jun, Dae Won제1저자Department of Internal Medicine, Hanyang University, Seoul Hospital, Seoul, South Korea
  2. Ahn, Sang BongDepartment of Internal Medicine, Nowon Eulji Hospital, Eulji University, Seoul, South Korea
  3. Kim, Tae YeobDepartment of Internal Medicine, Guri Hospital, Hanyang University, Guri, South Korea
  4. Sohn, Joo Hyun교신저자Department of Internal Medicine, Guri Hospital, Hanyang University, Guri, South Korea
  5. Kim, Sang GyuneDepartment of Internal Medicine, Bucheon Hospital, Soon Chun Hyang University, Bucheon, South Korea
  6. Lee, Se WhanDepartment of Internal Medicine, Cheonan Hospital, Soon Chun Hyang University, Cheonan, South Korea
  7. Kim, Byung HoDepartment of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University, Seoul, South Korea
  8. Kim, Dong JoonDepartment of Internal Medicine, Chuncheon Sacred Heart Hospital, Hallym University, Chuncheon, South Korea
  9. Kim, Ja KyungDepartment of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University, Seoul, South Korea
  10. Kim, Hyoung SuDepartment of Internal Medicine, Gangnam Severance Hospital, Yonsei University, Seoul, South Korea
  11. Hwang, Seong GyuDepartment of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, South Korea
  12. Choi, Won ChoongDepartment of Internal Medicine, Sanggye Paik Hospital, Inje University, Seoul, South Korea
  13. Tak, Won YoungDepartment of Internal Medicine, Kyungpook National University Hospital, Kyungpook National University, Daegu, South Korea
  14. Lee, Heon JuDepartment of Internal Medicine, Yeungnam University Medical Center, Yeungnam University, Daegu, South Korea
  15. 윤기태Department of Internal Medicine, Yangsan Hospital, Pusan National University, Yangsan, South Korea
  16. Yun, Byung CheolDepartment of Internal Medicine, Gospel Hospital, Kosin University, Pusan, South Korea
  17. Lee, Sung WookDepartment of Internal Medicine, Dong A University Medical Center, Dong A University, Pusan, South Korea
  18. Baik, Soon KooDepartment of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University, Wonju, South Korea
  19. Park, Seung HaDepartment of Internal Medicine, Haeundae Paik Hospital, Inje University, Pusan, South Korea
  20. Park, Ji WonDepartment of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University, Anyang, South Korea
  21. Park, Sol JiDepartment of Clinical Pharmacy, Graduate School of Clinical Pharmacy, Sungkyunkwan University, Suwon, South Korea
  22. Lee, Ji SungClinical Research Center, Asan Medical Center, Seoul, South Korea

초록

Background: Until now, various types of combined therapy with nucleotide analogs and pegylated interferon (Peg-INF) in patients with hepatitis B patients have been tried. However, studies regarding the benefits of de novo combination, late-add on, and sequential treatment are very limited. The objective of the current study was to identify the efficacy of sequential treatment of Peg-INF after short-term antiviral treatment. Methods: Between June 2010 and June 2015, hepatitis B e antigen (HBeAg)-positive patients (n = 162) received Peg-IFN for 48 weeks (mono-treatment group, n = 81) and entecavir (ETV) for 12 weeks with a 48-week course of Peg-IFN starting at week 5 of ETV therapy (sequential treatment group, n = 81). The primary endpoint was HBeAg seroconversion at the end of follow-up period after the 24-week treatment. The primary endpoint was analyzed using Chi-square test, Fisher's exact test, and regression analysis. Results: HBeAg seroconversion rate (18.2% vs. 18.2%, t = 0.03, P = 1.000) and seroclearance rate (19.7% vs. 19.7%, t = 0.03, P = 1.000) were same in both mono-treatment and sequential treatment groups. The rate of alanine aminotransferase (ALT) normalization (45.5% vs. 54.5%, t = 1.12, P = 0.296) and serum hepatitis B virus (HBV)-DNA <2000 U/L (28.8% vs. 28.8%, t = 0.10, P = 1.000) was not different in sequential and mono-treatment groups at 24 weeks of Peg-INF. Viral response rate (HBeAg seroconversion and serum HBV-DNA <2000 U/L) was not different in the two groups (12.1% vs. 16.7%, t = 1.83, P = 0.457). Baseline HBV-DNA level (7 log(10)U/ml vs. 7.5 log(10)U/ml, t = 1.70, P = 0.019) and hepatitis B surface antigen titer (3.6 log(10)U/ml vs. 4.0 log(10)U/ml, t = 2.19, P = 0.020) were lower and predictors of responder in mono-treatment and sequential treatment groups, respectively. Conclusions: The current study shows no differences in HBeAg seroconversion rate, ALT normalization, and HBV-DNA levels between mono-therapy and sequential therapy regimens.

키워드

EntecavirHepatitis BPeginterferon Alfa-2aPEGINTERFERON ALPHA-2ACOMBINATION THERAPYLAMIVUDINETRIAL

식별자

Scopus EID
2-s2.0-85049868704
WoS UID
000438436100002